Comment in

• Newly licensed drugs.

  Ferner RE. Ferner RE. BMJ. 1996 Nov 9;313(7066):1157-8. doi: 10.1136/bmj.313.7066.1157. BMJ. 1996. PMID: 8963199 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. Reducing frequency and severity of relapses will be of great clinical benefit.

  Burnfield A. Burnfield A. BMJ. 1997 Feb 22;314(7080):600. BMJ. 1997. PMID: 9055727 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. Current policy is sensible.

  Price C. Price C. BMJ. 1997 Feb 22;314(7080):600-1. BMJ. 1997. PMID: 9055728 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. Interferon beta reduces overall relapse rate by one third.

  Napier JC. Napier JC. BMJ. 1997 Feb 22;314(7080):601. BMJ. 1997. PMID: 9055729 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. Avoidance of the need for social care should also be taken into account.

  Holmes J. Holmes J. BMJ. 1997 Feb 22;314(7080):601. BMJ. 1997. PMID: 9055730 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. NHS Executive issued advice to help NHS plan for introduction of the treatment.

  Winyard G. Winyard G. BMJ. 1997 Feb 22;314(7080):601-2. BMJ. 1997. PMID: 9055731 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. Relapses deserve treatment.

  Cardy P. Cardy P. BMJ. 1997 Feb 22;314(7080):602. BMJ. 1997. PMID: 9055732 Free PMC article. No abstract available.
• Interferon beta in multiple sclerosis. Some form of compromise must be accepted.

  Peltola J, Keranen T. Peltola J, et al. BMJ. 1997 Feb 22;314(7080):602. BMJ. 1997. PMID: 9055733 Free PMC article. No abstract available.